Onconetix Announces 1-for-10 Reverse Stock Split to Maintain Nasdaq Listing
ONCO is trading near its 52-week low of $0.116 (4.8% below the low) on elevated volume (13× avg).
Summary
Onconetix announced a 1-for-10 reverse stock split, effective May 21, 2026, to meet Nasdaq's minimum bid price requirement and avoid delisting.
Key Events · Corporate Governance and Compliance · ONCO
-
Reverse Stock Split Finalized
The Board of Directors approved a 1-for-10 reverse stock split, effective May 21, 2026, following shareholder authorization on April 30, 2026.
-
Nasdaq Compliance Measure
The primary purpose of the reverse split is to bring the company into compliance with Nasdaq's minimum bid price requirement, preventing potential delisting.
-
Significant Share Count Reduction
The reverse split will reduce the number of outstanding common shares from approximately 11.4 million to 1.14 million.
-
Cash for Fractional Shares
No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment based on the closing price prior to the effective date.
Analysis · ONCO · Life Sciences
Onconetix has finalized a 1-for-10 reverse stock split, effective May 21, 2026, primarily to regain compliance with Nasdaq's minimum bid price requirement. This action follows shareholder approval on April 30, 2026, and is a critical step for the company to maintain its stock exchange listing. The company has previously disclosed a going concern warning and significant dilution, and its stock is currently trading near 52-week lows, underscoring the urgency and defensive nature of this move.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 36.1% of the 1753 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.04%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONCO was trading at $0.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.12 to $42.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.